INTRODUCTION
Chronic diseases, including MG, may have psychiatric consequences in terms of coping and adaptation. 1-2-3 Psychiatric morbidity usually appears as anxiety disorders, such as panic disorder and generalised anxiety disorder, and as depressive disorders. The interaction between MG and psychiatric disorders needs to be appreciated, especially in the primary care setting, since the symptoms may overlap. 4-5-6 MG may be under-recognised initially because the psychiatric symptoms may coincide with those of the actual disease, such as fatigue, lack of energy and shortness of breath. 7-8-9-10 On the other hand, co-morbid psychiatric symptoms that appear during the course of the illness may be misdiagnosed as true myasthenic symptoms; thus, leading to unnecessary drug treatment 30-31--32 . Differentiation of the aetiology of these symptoms might alter the treatment choice and, therefore, affect the treatment success rate and patients' wellbeing [33] [34] . Psychiatric treatments must be carefully planned because of the risk of aggravating the underling neurological disease. Even though there appears to be an intricate relationship between MG and psychiatric symptoms, there is very limited information on this subject. There is evidence that in MG patients, cholinergic transmission in the central nervous system (CNS) is also affected. This evidence includes observations of reduced REM sleep. electroencephalographic changes, and detection of Ach receptor antibodies in the cerebrospinal fluid of MG patients. Also, there are some studies on the mental status of MG patients. They manifest higher trait anxiety and greater suppression of anger, and nearly 20% of them were initially diagnosed as having a psychiatric disorder. They may show cognitive impairment as well. Acetylcholine is related to several mental disorders, including mood and cognitive disorders. 41 It is reported that MG patients manifest higher levels of trait anxiety. They also may inhibit the expression of anger. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] A retrospective study of MG patients revealed that almost 20% of them had initially received a psychiatric diagnosis. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] Young women are at increased risk to receive a diagnosis in this way. Depression seems to be related to the dose of anticholinesterase treatment needed and the self-reported muscular weakness. 43-46-47 Apart from "pure" psychiatric symptomatology, it seems that MG patients manifest lower Mini-Mental State Examination scores and also score lower in various memory tests. 44-48-49 MG patients may suffer from a disorder of higher cognitive functioning that responds to therapeutic intervention. 45-50-51 Between 20% and 30% of MG patients are initially misdiagnosed with a psychiatric illness. 60-52-53-54 Perhaps even more clinically significant, symptoms of depression among individuals already diagnosed with MG may be dismissed as symptoms of the neurological disease, thus delaying appropriate treatment of the mood disturbance. 55-56-57 
OBJECTIVE:
To determine the prevalence of depression among Sudanese patients with myasthenia gravis seen in Elshaab Teaching Hospital from January to September 2009.
METHODOLOGY:
This is a descriptive, prospective, hospital based, cross sectional study. It was conducted at El Shaab Teaching Hospital which is a tertiary hospital, located in the centre of Khartoum town. There are two neurological units with 43 beds and two neurosurgical units with 50 beds, there are three intensive care units, two neurology referred clinics and three neurosurgery referred clinics each week .A total number of 33 patients with myasthenia gravis were included in the study. The period of the study was from January 2009 to September 2009.Inclusion criteria: All Sudanese patients with myasthenia gravis ,their age above a18 years ,admitted or referred to Elshaab Hospital during the period of the study were included . Exclusion criteria: Non Sudanese patients, those below 18 years of age , or those who refused to be included in the study, were excluded. The data was collected by the authors using structural questionnaire. The informers were either the patients or close relatives. A full detailed history was taken from each patient, the history included: Age, Sex, origin, symptoms of weakness, drooping of the eyelids, double vision, difficulty of swelling, nasal speech and related neurological and systemic symptoms (disturbance of high cerebral function, syncope, motor and sensory defect, sphincter defects, symptoms infavour of cranial nerve involvement). Also past medical history (similar illness, psychiatric illness, autoimmune disease, rheumatoid arthritis, hypertension and DM), drugs history, family history (similar illness, neurological illness, autoimmune disease) and social history were taken. 
Limitations of the study:
The explanatory power of the study was limited by its small sample size .A further limitation related to the duration of the study which was short (The period of the study was from January 2009 to September 2009).
Results:
Regarding sex distribution among our studied group, females represent 70% & males 30%. It was found that 12 females had depression while 3 males had depression. 
DISSCUSION
It did appear that 45% of our patients had an evidence of depression, this is similar to what was mentioned by RobertH.Paul, Ronald A et al inspite of using different methodology to assess depression among their studied group ( CMDI ; Chicago Multiscale Depression Inventory : vegetative scale was used in this study to assess symptoms of depression). 63 Our study was differed from what was reported by Fisher, Justin et al where they found that 33% of their patients with MG were depressed. 64 Also it was differed from study done by Magnei etal where they found that 32% of their patients were depressed .The difference is due to the fact that Magnei study was analyzed by psychiatrist. It was found that 30% of our patients had major depression, & 15% had minor depression, these findings were not consistent with what was reported by other researchers. 64 The differences were due to the fact that the occurrence of depression among our studied group was due to other factors rather than MG itself ie: availability & cost of the drugs, compliance, level of education, cultural & environmental factors. Also variation in depression rate may be due to the use of different measures of depression, or depression measures that confound symptoms of disease activity with common features of depression (egg fatigue).The other possibility is the fact that the previous studies may be limited by small sample sizes. Like what was mentioned in literature females were affected with MG more than males. 11-12-13 the study showed that the prevalence rate of depression was higher among females which is keeping with what was mentioned in the literature. 14-61-62 Similar to what was reported by Andreas Hinz etal, our study showed that the age group (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) was more affected with MG , while the prevalence of depression was found to be higher among the age group (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) .Inspite of the fact that the study was conducted in Khartoum, most of patients with MG were seen from western Sudan , this raises the need for genetic,enviromental studies. However the prevalence rate of depression among those from western Sudan appeared to be less than among those from Khartoum,this may reflect true variation in the determinants of depression related to environmental, cultural, nutritional, racial or genetic factors. It was observed that most of our patients were house wives, with the prevalence of depression was higher among them, this may raise the possibility that job satisfaction can play a role in minimization of occurrence of depression. The frequency of depression was found to be higher early in the disease & decrease as duration increase, this unlike what was mentioned by Robert H.Paul et al. 63 This may be due to the fact that Sudanese patients face a lot of problems concerning the use of drugs, compliance, cost &availability of drugs, also incorporation between psychatrist& neurologist may contribute to that. In addition, social stigma of chronic diseases in our society may raise the prevalence rate of depression. Like what was mentioned in the literature higher prevalence of depression was found among those with generalized type of MG, 10 patients as compared with 5 patients with ocular type. 15-16-17 This may reflect the fact that patients with generalized MG facing complications like dysphagia and respiratory muscles paralysis. 19-18-20 Our study found that, associated diseases with MG ,don't affect the prevalence of depression, this unlike what was reported by other researchers and can be explained by the fact that our study was limited by small size sample. The study showed that out of 33 patients with MG two had thymoma, only one had depression & from this it seems that the number of patients with thymoma is few to a degree that it cannot be used in the analysis to support the idea that the presence of thymoma increase the chance of depression among patients with MG.Most of our patients found to have depression (10 patients) , showed no or mild response to treatment of MG , while 4 showed moderate response & only 1 patient showed marked response ( following thymectomy). This may reflect the effect of depression on the course & out come of MG (as one of chronic illnesses), this is similar to what was reported by Wells et al where they found that patients with a recent diagnosis of depression perceived their general health as poorer than subjects without a psychiatric disorder, even when controlling for the presence of chronic illness. Depression was also associated with significant limitation in physical functioning. [21] [22] The role of Ach in higher cognitive function is well studied and established. 46-54-23 However, this is not so concerning a possible role for Ach in the pathogenesis of depression. The Ach role in depression (if any) is not well studied. The inhibition of behavior produced by some agents (e.g., physostigmine) that are known to increase central Ach activity suggests that an Achnorepinephrine imbalance is central in the pathogenesis of depression. 55-24-25 However, other authors propose a relationship only to personality traits. 56-26-27-28 It has also been suggested that the simultaneous increase reported in the activity of catecholamines and in measurements that reflect the hypothalamus-pituitary-adrenal axis in depressed patients indicates, in fact, an increase of Ach activity. The increase of the central cholinergic basal activity after the administration of centrally active agents like physostigmine, arecholine, and oxotremorine usually triggers or worsens the behavioral analogs of depression. Many authors suggest that pharmacologically induced changes in Ach activity could lead to the development of a model of depression by influencing other transmitter systems (e.g., GABA, serotonin, dopamine, or norepinephrine). 29 
